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Summary Inherent and induced resistance was investigated in human small-cell lung cancer xenografts.
Specimens from three patients were established in immune suppressed mice; the sensitivity of the xenografts
to cyclophosphamide, MeCCNU and melphalan was determined using the growth delay end-point. Clinical
chemosensitivity data were available in two cases and inherent differences in sensitivity were noted both in the
xenografts and clinically. Radioactively labelled melphalan uptake studies were performed with these two
xenografts. A number of different strategies to induce resistance were explored. Only one method proved to
be successful and in only one of the xenografts; this was with cyclophosphamide. The induced resistant line
was characterised in terms of the time course of its production, the degree of induced resistance, the growth
rate, the cross-resistance pattern and stability of the phenotype; the possibility of altered antigenicity was also
examined.
Although induced resistance to cytotoxic
chemotherapy is a widely accepted phenomenon,
there have been few quantitative studies of the rate
at which resistance develops on repeated treatment
in human tumours. Sampling and measurement
problems contribute to the limitation of such
studies; ease of sampling reduces these problems in
the case of haematological malignancies (Steuart &
Burke, 1971). Resistance is by no means a universal
phenomenon and when patients who achieved
complete remission are treated again in relapse with
the same drug regime, second responses are
sometimes observed (Fisher et al., 1977).
The present study grew out of the work of
Shorthouse et al. (1980) who succeeded in
establishing 15 small-cell bronchial carcinoma
xenograft lines and comparing the
chemotherapeutic response of 6 of these with the
clinical response of the donor patient. For the
present work, 3 of the lines established by
Shorthouse (designated HX72, HX78 and HX88)
have been exposed to repeated drug treatment and




The donor of HX72 initially received radiotherapy
to the primary site of a small-cell carcinoma of the
lung. Subsequent recurrence of disease, as s.c.
nodules, was treated with a combination of
*Present address: Department of Radiotherapy, St
Bartholomew's Hospital, West Smithfield, London ECIA
Correspondence: R. Berman.
Received 13 September 1983; accepted 12 December 1983.
cyclophosphamide, CCNU and methotrexate but
this elicited only a poor partial response. A tumour
specimen was taken from a s.c. nodule and
established as a xenograft, after chemotherapy had
been given.
The donor of HX88 also received radiotherapy to
a lung lesion. Subsequently a right supraclavicular
fossa mass developed and when this was removed
for diagnostic purposes, a specimen was established
as a xenograft. The patient showed a complete
response to ifosphamide but later relapsed. Further
chemotherapy with mAMSA and VP-16 was tried
without success. The post mortem histology was
reported as a mixed small-cell and large-cell
anaplastic carcinoma of the bronchus.
The donor of HX78 had disseminated small-cell
carcinoma at diagnosis. Tumour material obtained
at bronchoscopy was established as a xenograft.
The disease progressed rapidly and chemotherapy
was not given.
Xenograft technique
Details of xenograft establishment have been
reported previously (Shorthouse et al., 1980).
Briefly, tumour pieces 50mg in weight were
implanted by bilateral s.c. implants in the posterior
flank of female CBA/lac mice. Mice used
throughout this work were immune-suppressed by
thymectomy, cytosine arabinoside treatment and
whole body irradiation, as described by Steel et al.
(1978).
Tumours were treated when they reached a
median volume of 150-200mm3 (calculated by the
formula 7r/6 x D xd2, where D was the largest
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superficial diameter and d was the superficial
diameter perpendicular to D). Growth curves were
plotted and the time taken for treated and control
groups to double in volume was obtained. Tumour
growth delay was calculated as the difference
between these values and when divided by the
control doubling time yielded an estimate of what
we have termed specific growth delay (Kopper &
Steel, 1975). This value can be regarded as the
number of volume doubling times by which
treatment delays tumour growth.
The conventional histology appearances of all 3
xenografts was of human small-cell cancer only.
Electron microscopy of 2 of the xenografts, HX78
and HX72, gave results consistent with the light
microscopy findings. Cytogenetic studies revealed a
human karyotype in each case.
Chemotherapeutic agents were given by i.p.
injection. Cyclophosphamide (Farmitalia Carlo
Erba Limited, Montedison Group), hereafter
referred to as CMD, was prepared as an aqueous
solution at 10mgml-'. MeCCNU (obtained from
the Cancer Treatment Division, N.C.I., Bethesda,
U.S.A.) was made up at 2mgml-' in a detergent
vehicle that consisted of 0.5ml DMSO plus 4.5ml
of 5% Tween 80. Control experiments showed that
the vehicle had no significant effect on the growth
of xenografts. Melphalan (Wellcome Foundation
Limited) was dissolved at 0.25mgml-1 in a
solution of 1 part 2% acid-alcohol plus 9 parts
normal saline. Vincristine (Eli Lilly Limited) was
given in an aqueous solution at 0.12mgml- .
X-ray treatment was given using a Pantak X-ray
machine operated at 200kV and 13 mA giving a
dose rate of approximately 2Gymin-1. For
irradiation, tumours were implanted as single
lumbo-sacral implants. The mice were restrained in
shielded holders that allowed irradiation without
anaesthetics. Half the dose was given from each
side of the animal.
Results
Figure 1 shows the dose-response curves for the
treatment of the 3 xenograft lines with
cyclophosphamide. The data in each case are
consistent with a linear dose response and it is clear
that two lines (HX78 and HX88) were more
sensitive to treatment as xenografts than was the
HX72 line; the difference in sensitivity is by a
factor of
- 4. As the drug dose was escalated some
tumours failed to regrow and regressed completely
(local control). It is for this reason that we have
used the median growth delay as our response
parameter. Local control was most evident with
HX88 (60% at 200mgkg-1) and HX78 (20% at
200 mgkg-1) but was virtually absent in HX72 over
CMD (mg kg-1)
Figure 1 Dose response curves obtained after
treatment with cyclophosphamide (CMD): *0=HX72;
* =HX78; * =HX88.
the dose range tested. Mortality generally increased
with drug dose. However mortality was not greater
in mice bearing the more resistant *tumour; the
LD50 was close to 250mgkg-1 for mice bearing
HX78 and HX72 whilst mice bearing HX88
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Similar experiments with MeCCNU showed that
HX72 was also 4-fold less sensitive than HX88.
On treatment with Melphalan, HX72 gave a
growth delay that was only half that found in
HX88 (P<0.01). When _1.0yCi of [14C]-
Melphalan was administered to mice bearing the
HX72 and HX88 xenograft lines no difference in
uptake was detected (HX72=1.23 x 10-2 and
HX88 = 1.33 x 102countsg-1min-1).
A number of different strategies to induce drug
resistance were examined. Cell survival studies with
HX88 showed exponential cell kill with no evidence
of a resistant component over the dose range of
CMD studied; this contrasts with the findings of
Valeriote et al. (1968) in a mouse lymphoma.
Attempts to establish xenografts from colonies
regrowing after high drug doses were unsuccessful.
In separate experiments mice bearing xenografts
were given 25mgkg-1 of CMD weekly for 6
treatments. When passaged into fresh hosts the
tumours showed a response to a single test dose of
50mgkg-1 CMD that was indistinguishable from
the response of control tumours that had received
no prior CMD treatment.
A larger series of experiments was performed
using high single-dose treatment, passaging the
best-regrowing tumours into fresh recipients after
each treatment. The results with HX78 (Figure 2)
showed that after the second treated passage the
response fell progressively until by the 8th treated
passage the median growth delay was
approximately one-eighth of that obtained with
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to achieve and even after this protracted regime the
response was not completely abolished.
In order to confirm the acquired resistance in
HX78, experiments were performed after 5 treated
passages in which the resistant line was grown in
one flank of a mouse and the previously untreated
sensitive line was implanted in the contralateral
flank. Results are shown in Figure 3 where it can
be seen that in the absence of treatment, the
resistant and sensitive tumours grew at the same
rate (volume doubling time about 6 days). When
the animals were treated with 50mgkg'I CMD the
resistant line showed a growth delay of less than
one volume doubling time, whilst the median
volume of the sensitive tumours showed no
tendency to regrow up to 18 days after treatment,
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Figure 2 Induction and stability of resistance in
HX78 treated with cyclophosphamide (CMD).
Induction ofresistance (closed circles) shown by growth
delay decrease after treatment with cyclophosphamide
in successive passages. Lack of stability (open circles)
shown by the increase in growth delay of untreated
controls tested with the same dose of
cyclophosphamide.
Figure 3 Confirmation of resistance. Comparison of
the senstitivity of HX78 and HX78Cy contralaterally
implanted in the same animal. The log rank test of
significance gave P=0.5 when controls of HX78 and
HX78Cy were compared but P<0.0001 for
comparison of the treatment groups of HX78 and
HX78Cy. There were 10 pairs of control xenografts
and 12 pairs of treated xenografts.434 R. BERMAN & G.G. STEEL
The strategy of using a single-dose treatment per
passage, as for HX78, was employed with other
small-cell carcinoma xenografts and also with
MeCCNU. In the case of HX72 and HX88 treated
with CMD these experiments gave no evidence of
progressively increasing drug resistance. Equally,
the treatments of HX78, HX88 and HX72 with
MeCCNU did not result in the appearance of
progressively increasing drug resistance. This is
perhaps not surprising in view of the lower initial
response of HX72 to CMD and of all 3 tumour
lines to MeCCNU but the surprise is HX88 which
initially was as sensitive as HX78 to CMD but
which failed to show induction of resistance.
The growth characteristics of the 3 xenograft
lines were similar. When estimated over a number
of experiments the median volume doubling times
were 6.0 days for HX72, 6.5 days for HX88 and 7.0
days for HX78. The CMD-resistant line of HX78
showed a growth rate that was indistinguishable
from the untreated line.
After 5 treatment passages a separate HX78
xenograft line was maintained without repeated
drug treatment. As shown in Figure 2 this line
retained its drug resistance through one further
passage without treatment and then rapidly
reverted to a sensitive response.
The results of cross resistance studies are shown
in Table I. The resistant line (HX78Cy) was not
only resistant to CMD but also to each of the other
agents tested.
Table I Results of cross resistance investigations
Xenograft Specific
Growth Delay
Agent Dose HX78 HX78Cy
MeCCNU l0mgkg-' 3.1 Nil
Melphalan 2.5mgkg-' 8.6 0.6
Vincristine 1.2mgkg-1 10.6 5.2
X-rays 2.0Gy 2.4 <0.5
In order to rule out the possibility that the
induction of CMD resistance produced a
concomitant decrease in the antigenicity in the
HX78Cy line, a series of immunization studies were
performed. Tumours were excised and chopped
finely into a tumour brei. This was sterilized using
a dose of 10OGy 60Co irradiation and volumes of
0.2ml were injected i.m. into the hind limb of mice;
two immunizations were given, separated by 7 days.
Figure 4 shows the tumour growth data for the
parent (HX78) line and the CMD resistant
(HX78Cy) line, each given either no immunization
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Figure 4 Examination of the effect of prior
immunization with non-viable HX78 (triangles), non-
viable HX78Cy (squares) or nothing at all (circles) on
the growth rate of viable HX78 (open symbols) and
viable HX78Cy (solid symbols).
or sensitive tumour line material. In neither case
was there evidence that this type of immunization
inhibited tumour growth.
Discussion
The present experiments demonstrate the two main
forms of drug resistance, inherent and induced, in
human small cell bronchial carcinoma.
The line designated HX72 came from a patient
after relapse following chemotherapy. The poor
partial response to combination chemotherapy in
the patient coupled with the evidence that the
xenografts were also relatively drug resistant
(Shorthouse et al., 1980, and the data presented
here) indicate that in this case inherent resistance to
CMD and MeCCNU was stable on xenografting
and did not disappear through 20 xenograft
passages. HX72 was also relatively resistant to
melphalan yet was found to have a similar uptake
of radioactively labelled melphalan when compared
with a more sensitive xenograft (HX88). These
results are in keeping with other reports onDRUG RESISTANCE IN SMALL-CELL BRONCHIAL CARCINOMA 435
melphalan uptake in human tumours of different
chemosensitivity (Wist et al., 1981; Parsons et al.,
1981).
Induced resistance to chemotherapy is a variable
phenomenon. The two small cell bronchial
carcinoma lines, both taken from previously
untreated patients, showed a similar responsiveness
as xenografts when treated with identical doses of
CMD. However, under the same schedule of
repeated drug treatments, resistance progressively
developed in one line (HX78) but not in the other
(HX88). Concurrent experiments with doses of
MeCCNU that were judged to give a similar level
of response, in each of the 3 xenografts, did not
lead to the induction of resistance. In the case of
HX78 where resistance was induced against CMD
but not against MeCCNU, the initial treatment (of
the repeat treatment schedule) produced a larger
response with CMD than with MeCCNU.
Comparison of the relative ability of these two
drugs to induce resistance is therefore difficult.
The 8-fold reduction in response to CMD of
HX78 took over a year to achieve and even after
this protracted period of treatment the response
was not completely abolished with the drug dose
employed. This finding may possibly be explained
by properties specific to the model system,
chemotherapy schedule or the tumour's inherent
inability to rapidly alter its level of response.
However, use of other schedules, drugs and
tumours suggests that resistance is not readily
induced in small-cell lung cancer xenografts. Other
laboratory investigations of human tumours have
shown that resistance may take many months to
induce (Parsons & Morrison, 1978; Ohnoshi et al.,
1982) though others have taken very much shorter
times (Beck et al., 1979; Houghton et al., 1981).
Hodgkins Disease patients relapsing after achieving
an initial CR with MOPP, when treated again with
MOPP achieved a second CR in 56% of cases
studies by De Vita's Group (Fisher et al. 1977).
The evidence for stability in the inherently
resistant HX72 contrasts with the data on HX78
(Figure 2) which show that the resistance induced
in this xenograft line largely disappeared within two
passages without treatment. It therefore appears
that drug resistance in HX72 and HX78Cy was
basically different in type. The nature of this
difference remains to be elucidated. The lack of
stability in HX78Cy might imply that some sort of
adaptive change had occurred. It is also possible
that HX78 contained both resistant and sensitive
elements from the onset and that the sensitive
component was not completely eradicated by
treatment. Some form of growth advantage for the
sensitive cells may have allowed them to grow out
when treatment was discontinued.
Non-stable resistance to methotrexate in small
cell bronchial carcinoma cells has also been
reported recently (Curt et al., 1983). There was
evidence that in this case the explanation lay in the
location of genes coding for dihydrofolate reductase
on double minute chromosomes which, since they
lack centromeres, could be progressively lost by
failure to segregate during cell division. Unstable
resistance in human fibrosarcoma and epidermal
carcinoma cells to interferon has also been reported
(Lin et al., 1982). These results contrast with a
large body of data that document the stability of
drug-induced resistance (Ohnoshi et al., 1982;
Houghton et al., 1981; Parsons et al., 1982).
The clinical implications of these observations are
that the occurrence of induced drug resistance may
vary from one patient to another and perhaps from
one treatment to another. It may take a long time
to induce and possibly be lost quickly. It therefore
may not always be right to abandon a treatment
that initially was effective. This could be an area
where the availability of a rapid in vitro
chemosensitivity test would offer significant clinical
advantages.
The data shown in Table I indicate that the
resistant line was also cross resistant to each of the
other agents tested, including radiation. This is
therefore a further reason why switching from the
first choice drug treatment would in this tumour
probably be unwise.
Immunohistochemical studies were performed
using an antikeratin antibody which demonstrated
the presence of keratin in HX72 and HX78Cy, the
inherent and the induced resistant lines, but
essentially none in the two sensitive lines (HX78
and HX88). The results of these investigations and
further tissue analysis will be presented in more
detail in a separate communication. These results,
taken with the cross-resistance data, lead to a
possible mechanism for the drug resistance in these
small-cell bronchial cancer xenografts. Although
conventional light microscopy examination of the
original HX72 and HX78 tumours was reported as
pure small-cell carcinoma, it seems likely that they
contained squamous carcinoma elements or the
potential for their production. In the case of HX78
these non-small-cell components were insufficiently
developed to influence the initial response to CMD
but could be induced by repeated drug treatment.436 R. BERMAN & G.G. STEEL
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